UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody
UCB obtains worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases Deal ...
HONG KONG and BRUSSELS, March 4, 2026 /PRNewswire/ -- Antengene Corporation Limited (Antengene), a leading innovative, commercial-stage global biotech company, and UCB, a global biopharmaceutical ...
UCB secured worldwide exclusive rights to develop, manufacture, and commercialize ATG-201, including access to Antengene’s enabling manufacturing technology for this bispecific T-cell engager modality ...
Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases.
TOKYO, JAPAN, February 10, 2026 /EINPresswire.com/ — Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, hereafter “Chugai”) and Araris Biotech AG (hereafter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results